Survival ON BREAST CANCER PATIENTS WHO HAVE NEGATIVE triple adjuvant chemotherapy GET CANCER IN THE INSTALLATION OF INTEGRATED TULIP DR. Sardjito
ABSTRACT: Background Breast cancer is the leading cause of morbidity and mortality of cancer in women worldwide. Triple negative breast cancer have a poorer prognosis than other types because of more aggressive and do not have a targeted therapy. Up to now there is no data on overall survival triple negative breast cancer patients and the role of chemotherapy on survival of triple negative breast cancer in Indonesia Objective The primary endpoint of this study was to assess overall survival (OS) and disease free survival (DFS) of triple negative breast cancer in our routine clinical practice. The secondary endpoint was to assess factors that affect the prognosis, such as age, tumor size, lymph node involvement, stadium, regimen chemotherapy. Results Eighty subjects were followed with a median duration of 40 months. The estimated overall survival (OS) rates at 3 years were 95% and disease-free survival (DFS) rates at 3 years were 75% among patients tripl negative breast cancer who receive adjuvant chemotherapy. Our OS and DFS rate study were lower than other studies. Age <40 year has a significant level of OS and DFS 3 years lower than the age >=40 years. Tumor size (T)does not affect the level of 3year OS and DFS. The degree of lymph node involvement (N) does not affect OS 3 years but affect DFS 3 years. Stadium not affect the level of 3-year OS and DFS. Types of chemotherapy regimens result better OS and DFS can not be known at this time as the analysis of the type of chemotherapy regimen with OS and DFS was not obtained significance. Compared to other studies, age and stage affects OS and DFS, while the lymph nodes involvement, tumors did not affect OS and DFS Conclusion Our research during a median follow-up of 40 months obtain that 3-year OS is 95% (mean OS 35,8 months) and 3-year DFS is 75% (mean DFS 30 months). Age <40 years and lymph node involvement confers a poor prognosis in our study. Need to do research on the molecular biology of triple negative breast cancer characteristics that affect prognosis and checked prior to therapy to get the better treatment in the future.
